<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>04342naa a22006497i 4500</leader>
  <controlfield tag="001">UMUN-OA-20261005-MLS-032</controlfield>
  <controlfield tag="003">local</controlfield>
  <controlfield tag="005">20261005174904.0</controlfield>
  <controlfield tag="006">m     o  d        </controlfield>
  <controlfield tag="007">cr||||||||||||</controlfield>
  <controlfield tag="008">261005s2023    xx      o    u000 0 eng d</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="a">10.1186/s12967-023-04292-3</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(local)EuropePMC:PMC10327392</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">local</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">local</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1="0" ind2=" ">
    <subfield code="a">Gunjan Dagar</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. /</subfield>
    <subfield code="c">Gunjan Dagar; Ashna Gupta; Tariq Masoodi [and others].</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
    <subfield code="a">[Place of publication not identified] :</subfield>
    <subfield code="b">BMC,</subfield>
    <subfield code="c">2023.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 online resource (1 article).</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
    <subfield code="a">text</subfield>
    <subfield code="b">txt</subfield>
    <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
    <subfield code="a">computer</subfield>
    <subfield code="b">c</subfield>
    <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
    <subfield code="a">online resource</subfield>
    <subfield code="b">cr</subfield>
    <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">The source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publication type: Review article.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Linked open-access copy: published version.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Open access; no subscription required for the linked open-access version.</subfield>
    <subfield code="f">Unrestricted online access</subfield>
    <subfield code="2">star</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution. See the linked licence for the applicable terms.</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/</subfield>
  </datafield>
  <datafield tag="546" ind1=" " ind2=" ">
    <subfield code="a">In English.</subfield>
  </datafield>
  <datafield tag="588" ind1="0" ind2=" ">
    <subfield code="a">Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">Course allocation: B. Sc. Medical Laboratory Science.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Tumor antigens</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Immunotherapy</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Hematological malignancy</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Solid tumor</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Cytokine Release Syndrome</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Antigen Escape</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">B. Sc. Medical Laboratory Science</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">UMUN open access collection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">hematology</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">Review articles.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Ashna Gupta</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Tariq Masoodi</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Sabah Nisar</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Maysaloun Merhi</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Sheema Hashem</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Ravi Chauhan</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Manisha Dagar</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Sameer Mirza</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Puneet Bagga</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Rakesh Kumar</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Ammira S Al-Shabeeb Akil</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="t">Journal of translational medicine</subfield>
    <subfield code="g">Vol. 21, no. 1, (2023), pages/article 449</subfield>
    <subfield code="x">1479-5876</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">https://europepmc.org/articles/PMC10327392</subfield>
    <subfield code="y">Read open-access publication</subfield>
    <subfield code="z">Open access.</subfield>
    <subfield code="7">0</subfield>
  </datafield>
  <datafield tag="884" ind1=" " ind2=" ">
    <subfield code="a">Course selection and automated MARC21 enrichment from Europe PMC metadata.</subfield>
    <subfield code="g">20261005</subfield>
    <subfield code="k">https://europepmc.org/articles/PMC10327392</subfield>
    <subfield code="q">local</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="n">0</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">1174</subfield>
    <subfield code="d">1174</subfield>
  </datafield>
</record>
